Sanofi

News

People with early type 1 diabetes in England and Wales will soon be able to access Sanofi's Tzield, which can delay the need for insulin injections.

News

Paulo Fontoura, currently chief medical officer of Xaira Therapeutics, will replace Houmab Ashrafian as Sanofi's R&D head on 1st September.

News

Sanofi's on-body injector version of multiple myeloma therapy Sarclisa has been cleared in the UK, which will be the first market for the product.

News

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.

Digital

At the PharmStars Pharmtech Innovation Summit in Boston, start-up founders and pharma executives shared the stage to share lessons on AI deployment.

News

The FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.